Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose oral dydrogesterone to improve endometrial receptivity in recurrent implantation failure
ChiCTR2100042171Phase 4Recruiting
- Sponsor
- Zhejiang Provincial People's Hospital
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dydrogesterone in Recurrent Implantation Failure (RIF), sponsored by Zhejiang Provincial People's Hospital. Primary endpoint: P+6 day pinocytosis count and pinocytosis index. Started Jan 2021; status: recruiting.
02
Drugs
dydrogesterone
03
Conditions
Recurrent Implantation Failure (RIF)
Beyond the preview
Go deeper on ChiCTR2100042171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100042171.